Alligator Bioscience (ATORX) investor relations material

Executive summary

• Final phase II data for mitazalimab in first-line metastatic pancreatic cancer presented, showing promising efficacy and survival benefits, supporting advancement to registrational phase III development, with new mechanistic insights presented at major scientific meetings.

• Signed a letter of intent with Unicancer to explore an investigator-sponsored phase III study for mitazalimab, aiming to reduce trial costs while maintaining regulatory quality.

• Ongoing partnering discussions, especially with companies developing KRAS inhibitors, to explore combination therapies and differentiation opportunities.

• Continued progress in partner programs, including HLX22 and new bispecific antibody HLX49, with multiple clinical trials underway and first patient dosed in HLX22 phase II/III breast cancer study.

• Strengthened IP position for RUBY bispecific antibody technology.

Financial highlights

• Operating costs for Q1 2026 were approximately SEK 17–17.8 million, with initial phase III costs included.

• Cash position at quarter-end was SEK 33 million, providing runway into mid-Q3 2026.

• TO 14 warrants exercised at a 38% rate, generating SEK 90 million in gross proceeds, with SEK 19 million reported as raised and partial loan repayment to Fenja Capital.

• Cost base reduced from SEK 300 million annualized to SEK 100 million, with further reductions expected.

• Net sales for Q1 2026 were SEK 0.5 million, down from SEK 1.4 million in Q1 2025.

Outlook and guidance

• Phase III feasibility assessment ongoing, with trial initiation targeted for Q4 2026, pending regulatory and contractual finalization.

• Exploring various financing options, including licensing, grants, and additional capital raising, to support ongoing operations and phase III trial costs.

• Expectation of additional clinical trials in other indications, including biliary tract cancer, during 2026.

• Focus remains on advancing mitazalimab to registrational development and preserving HLX22 value without incurring development costs.